The Mesothelioma Stratified Therapy (MiST) trial is a British Lung Foundation funded, University of Leicester study – a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.
MiST is a stratified multi-arm phase IIa clinical trial to enable accelerated evaluation of targeted therapies for relapsed malignant mesothelioma. The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving survival outcomes for patients with mesothelioma. Arm 2 will open from July followed by arms 3 and 4 (arm 1 is now closed to recruitment).
Professor Dean Fennell, Chair of Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Research Programme, University of Leicester and University Hospitals of Leicester NHS Trust said: “The MiST study (arm 1) recruited its first patient in February 2019 and there has been rapid recruitment into the first arm of the study. This trial confirms expectations about the potential of MiST to accelerate personalised drug development in mesothelioma. We look forward to providing new treatment opportunities across the UK for patients, when the three new treatment arms open to recruitment this summer.”
The three new arms will open across multiple centres Newcastle, Manchester, Leicester, Southampton and the Royal Marsden to give nationwide coverage.
Contact email@example.com for further details.